RevenueShares Ultra Dividend ETF

Latest RevenueShares Ultra Dividend ETF News and Updates

  • uploads///TGT Ratings
    Miscellaneous

    Did Analysts Change Their Views on Target after 1Q17 Results?

    The majority of analysts covering Target (TGT) remain neutral on the stock.

    By Amit Singh
  • uploads///Elacestrant market opportunity
    Company & Industry Overviews

    Taking Stock of Radius Health’s Licensing Agreements

    The market has responded very positively to Radius Health’s recent performance. In the past month, Radius stock has generated a 28% return for its shareholders.

    By Kenneth Smith
  • uploads///RDUS pipeline
    Company & Industry Overviews

    A Strong Pipeline of Drugs Bodes Well for Radius Health

    The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis.

    By Kenneth Smith
  • uploads///RDUS Analysts Reco
    Company & Industry Overviews

    Analysts’ Ratings for Radius Health and Its Peers in January

    In April 2017, Radius received FDA approval for its first commercial product, Tymlos. Tymlos was approved for the treatment of postmenopausal women with osteoporosis at a high risk for fracture.

    By Kenneth Smith
  • uploads///VTR DIV
    Industrials

    How Ventas’s Dividend Yield Compares

    Revenue and earnings Ventas (VTR) is a major REIT in the United States and Canada. The company’s revenue growth slowed from 18% in 2015 to just 5% in 2016. The growth was driven by all of its segments, through resident fees and services, office building and other service revenue, and income from loans and investments, […]

    By Amanda Lawrence
  • uploads///TGT Ratings
    Miscellaneous

    What Analysts Think of Target Stock

    The majority of analysts covering Target (TGT) are neutral on the stock. Analysts’ consensus rating on TGT was 2.9 on a scale of 1.0 (strong buy) to 5.0 (strong sell).

    By Amit Singh
  • uploads///A
    Company & Industry Overviews

    China Is Stabilizing through Policy Support

    OppenheimerFunds Make no mistake, China is a controlled economy where growth can still be manufactured at will. Massive fiscal and monetary stimulus has China going through a “mini” boom with the pace of economic growth stronger and more broad based than what the markets expected. And as China goes, so goes the rest of emerging […]

    By OppenheimerFunds
  • uploads///A
    Company & Industry Overviews

    Resilient Global Growth Supports Equities

    OppenheimerFunds Leading indicators of the global economy are climbing and that generally bodes well for equities. Previously, we highlight the tight fit between the JP Morgan Global Composite Purchasing Managers’ Index (black line, left axis)—a leading indicator of worldwide business activity—and the year-over-year returns of the MSCI All Country World Index (ACWI) returns since 2000. […]

    By OppenheimerFunds
  • uploads///
    Company & Industry Overviews

    We Are in a New World of Persistent Dollar Strength

    OppenheimerFunds That was then: For the longest time, we insisted that the strength of the dollar was the equalizer in a deleveraging world. If the Fed were to be the only major country in the world raising interest rates, then the dollar would appreciate significantly. Dollar strength would prove to be a headwind to U.S. […]

    By OppenheimerFunds
  • uploads///A
    Company & Industry Overviews

    U.S. Economic Drag Is Fading, Upside Surprises Are Possible

    OppenheimerFunds The U.S. economy was weaker than expected in 2016, the lagged effect of the Fed’s policy mistake in 2015. In our opinion, the worst is now over for the United States, and economic growth should improve in 2017 and could even surprise to the upside with an appropriate fiscal policy mix from the new […]

    By OppenheimerFunds
  • uploads///
    Company & Industry Overviews

    The Cycle Continues, but the Risks Are Rising

    OppenheimerFunds In response to accusations of flip-flopping, John Maynard Keynes purportedly quipped, “When the facts change, I change my mind. What do you do, sir?” With 2017 in full swing, the facts have changed. Since the financial crisis, the global economy has been mired in a slow growth, disinflationary world. We argued that the weak […]

    By OppenheimerFunds
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.